Merlino, D. J.
Barton, J. R.
Charsar, B. A.
Byrne, M. D.
Rappaport, J. A.
Smeyne, R. J.
Lepore, A. C.
Snook, A. E.
Waldman, S. A.
Funding for this research was provided by:
National Cancer Institute (1R01 CA204881, R01 CA206026, P30 CA56036)
National Institute of Neurological Disorders and Stroke (2R01NS079702, 1R56NS096028, F30NS103436)
National Institute of Diabetes and Digestive and Kidney Diseases (1F30DK103492)
Pharmaceutical Research and Manufacturers of America Foundation
Margaret Q. Landenberger Research Foundation
W. W. Smith Charitable Trust
Targeted Diagnostics and Therapeutics, Inc.
National Institute of Neurological Disorders and Stroke (1R01NS110084-01)
Article History
Received: 15 June 2018
Accepted: 24 August 2019
First Online: 4 September 2019
Compliance with ethical standards
:
: SAW is the Chair of the Scientific Advisory Board and member of the Board of Directors (both uncompensated) of Targeted Diagnostics & Therapeutics, Inc. which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work. He is a member of the Scientific Advisory Boards of Therapeutic Architects, Inc. and MLH Exploration, LLC (both uncompensated). He is a member of the Board of Directors of Feelux, Inc. (compensated).
: Human samples were provided by the Brain Tissue Donation Program at the University of Pittsburgh, via the NIH NeuroBioBank (IRB protocol # REN14120157/IRB981146). Additionally, the Institutional Animal Care and Use Committee at Thomas Jefferson University approved all animal studies described in this work.
Free to read: This content has been made available to all.